Medifast, Inc. Q1 2026 Earnings Recap

Shares rose 19.3% as the market rewarded Medifast for its initial signs of stabilization and sequential quarterly revenue growth after three years of decline, driven by solid coach productivity gains and progress in repositioning toward metabolic health.

Key Takeaways

• First quarter marked the first sequential quarterly revenue growth in three years, signaling a potential turnaround after an extended downturn.
• The number of active earning coaches continues to decline but was offset by a second consecutive quarter of year-over-year coach productivity improvements.
• Enhanced coach leadership and a higher percentage of coaches acquiring new clients indicate strengthening field engagement.
• The company has realigned its cost structure, targeting over $30 million of future savings to support reattaining profitability despite ongoing investments in long-term growth.
• Medifast is advancing its metabolic synchronization science, with new clinically backed products planned for rollout later this year, aiming to further differentiate in the shifting weight loss and metabolic health market.